You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 292 No. 2, July 14, 2004 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Grand Rounds at the NIAID and the Clinical Center of the NIH
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (10)
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Topic Collections
 •HIV/AIDS
 •Viral Infections
 •Drug Therapy
 •Adverse Effects
 •Gastroenterology
 •Liver/ Biliary Tract/ Pancreatic Diseases
 •Infectious Diseases
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

HIV Infection, Hepatitis C Infection, and HAART

Hard Clinical Choices

Shyam Kottilil, MD, PhD; Michael A. Polis, MD, MPH; Joseph A. Kovacs, MD

JAMA. 2004;292:243-250.

Abnormalities in hepatic function have become one of the most common complications occurring among human immunodeficiency virus (HIV)–infected individuals receiving highly active antiretroviral therapy (HAART), and liver disease has become an increasingly important cause of morbidity and mortality in HIV-infected patients. We present a case of a patient with HIV infection and hepatotoxicity that exemplifies the complications currently observed during the treatment of such patients. Hepatotoxicity can be a result of several factors, including a direct effect of HAART, substance abuse, and coinfection with either hepatitis C virus (HCV) or hepatitis B virus. Imaging studies may be helpful in determining the etiology; however, a liver biopsy is often necessary to be able to more accurately determine the relative contributions of different processes. Although coinfection with HCV and HIV has become a common clinical problem, optimal treatment of such patients remains to be defined and must be individualized to maximize benefit and tolerance.


Author Affiliations: Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (Drs Kottilil and Polis) and Critical Care Medicine Department, Warren G. Magnuson Clinical Center (Dr Kovacs), National Institutes of Health, Bethesda, Md.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Treatment of Hepatitis C in HIV-Coinfected Patients
Hughes and Shafran
The Annals of Pharmacotherapy 2006;40:479-489.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2004 American Medical Association. All Rights Reserved.